SciELO - Scientific Electronic Library Online

vol.30 issue6Pharmacokinetics of vancomycin in children hospitalized in a critical care unit author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand




Related links


Revista chilena de infectología

Print version ISSN 0716-1018


MOYA CORDERO, Patricia et al. Evaluation of the efficacy and safety of tigecycline for treatment of respiratory tract infections: Systematic review of literature. Rev. chil. infectol. [online]. 2013, vol.30, n.6, pp.591-597. ISSN 0716-1018.

Background: Tigecycline is indicated for the treatment of complicated skin infections, soft tissue and intraabdominal infections. Its use could be extended to community-acquired pneumonia (CAP) and hospital pneumonia (HN). The objective was to evaluate the efficacy and safety of tigecycline in the treatment of respiratory infections. Methods: systematic review (2012). Databases used were MEDLINE, EMBASE, Cochrane Library, CRD and WOK. We identified clinical trials of adults with respiratory infection, treated with tigecycline. The quality of the studies was assessed using CASPe checklist. Results: We selected four clinical trials of high-moderate quality. Three studies with patients with CAP and a trial with HN patients. In patients with CAP, efficacy of tigecycline (88.6 to 90.6%) was higher than levofloxacin (85.3 to 87.2%). The non inferiority testing was statistically significant (p < 0.001). In the study of patients with HN tigecycline showed an efficiency of 67.9% versus 78.2% for imipenem/cilastatin. Main adverse effects were gastrointestinal. Conclusions: The efficacy of tigecycline is non inferior than levofloxacin in patients with CAP, but less than imipenem in patients with HN. Tigecycline demonstrates noninferiority versus others tested antibiotics, and it shows a good safety profile.

Keywords : Tigecycline; nosocomial pneumonia; community-acquired pneumonia; systematic review.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )


Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License